View Financial HealthCannaPharmaRX 배당 및 자사주 매입배당 기준 점검 0/6CannaPharmaRX 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률4.4%자사주 매입 수익률총 주주 수익률4.4%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jan 14Cannapharmarx, Inc. Announces Resignation of Director Rick Orman, Effective January 8, 2026CannaPharmaRX, Inc. announced that on January 8, 2026, Rick Orman informed the Board of Directors of his resignation as a member of the Board effective immediately. Mr. Orman's resignation from the Board did not indicate it was the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies, or practices of the Company.공시 • Aug 22Cannapharmarx, Inc. Announces Revenue Guidance for Third Quarter 2025CannaPharmaRX, Inc. announced revenue guidance for third quarter 2025. The company projects revenues of approximately CAD 1,050,000, with the anticipation of additional shipments before the end of September. This forecast may vary slightly depending on fluctuations in the Euro-to-Canadian Dollar exchange rate.공시 • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/16/2025, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 02CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 04/01/2025, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Jun 06CannaPharmaRX, Inc. Announces CEO ChangesCannaPharmaRx, Inc. announced that the company has appointed a new CEO. Dean Medwid succeeds Domenic Colvin, who will stay with the company providing leadership and vision. Mr. Medwid assumed CEO duties earlier this month and will guide the company through its rapid growth phase. Mr. Medwid is a dynamic senior operations executive with more than thirty years of experience in both public and private markets with a focus on scalable process engineering, brand development and strategic partnerships. He has been recognized with numerous business awards and accolades, including Profit 100's Top 100 in Canada, five years in a row while a partner in Seattle's Best Coffee, additionally was a awarded the recognition of being one of Vancouver's Top 40 Under 40. Mr. Medwid recently exited his prior company in the retail cannabis sector and looks forward to bringing that background to the company as they target new revenue opportunities this year. His strengths include driving growth through the expansion of market segments and geography resulting in multi-year growth. Mr. Medwid also has extensive experience creating internal processes for departmental budgets, technology standards and human resource policies resulting in an engaged workforce as well as developing corporate governance aligned to generally accepted accounting principles. Mr. Medwid has a demonstrated history of increasing corporate performance through the management of process design, customer relationships, strategic planning along with a focused initiative of data-driven change management and utilized these skills as President of other successful publicly traded companies with operations in multiple countries.공시 • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/15/2024, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Mar 28CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 03/27/2024, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Nov 15CannaPharmaRX, Inc. announced delayed 10-Q filingOn 11/14/2023, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Oct 15CannaPharmaRX, Inc. Announces Executive ChangesEffective October 13, 2023, John Cassels is being replaced as the Chief Financial Officer (“CFO”) of CannPharmaRX, Inc. effective June 1, 2023. There was no disagreement between and Mr. Cassels on any matter related to operations, policies or practices that led to Mr. Cassels’s replacement as CFO. Effective October 13, 2023, Board of Directors has determined to appoint Oliver Foeste as Chief Financial Officer. Mr. Foeste has consented to such appointment. Mr. Foeste is the founder and Managing Partner of Invictus Accounting Group LLP and has significant executive, director, finance, and public company compliance experience across a number of industry sectors including cannabis and nutraceuticals. Prior to Invictus, Mr. Foeste was in senior finance and accounting roles at TSX, TSXV, and NYSE listed issuers, and earned his CPA at Deloitte and a boutique tax advisory firm.공시 • Aug 26CannaPharmaRx Expands Board of DirectorsCannaPharmaRX, Inc. announced that it has expanded its board of directors from three seats to five. The board deemed this expansion was in the best interest of the corporation as it coincides with an expansion of operations. The following person(s) were elected to the Board to fill the newly created directorships until the next annual meeting of stockholders of the corporation: Mr. Anthony Panek, age 38, is a corporate mergers and acquisitions attorney and venture capital investor with expertise in capital raising formation and growing businesses. He has worked with private equity and venture capital funds to allocate capital to emerging growth companies and works with emerging growth companies, both public and private, to raise capital and acquire assets and corporate talent. He has been an investor in many emerging growth companies and private funds investing in similar companies. He works with companies from a business and legal perspective to navigate and manage growth challenges facing emerging growth companies and helping companies complying with their SEC reporting obligations. He completed the Venture Capital Certificate Program at Startup@Berkeley Law. Mr. Panek was selected to serve on the Company's Board based upon his experience as an attorney and venture capital and private equity investor helping emerging companies raise capital, comply with SEC reporting and governance requirements, and his work with other cannabis companies. Mr. Adam Mindle, age 52, is a transactional attorney with extensive experience in structuring, negotiating and documenting sophisticated joint ventures, secured financing and mergers and acquisitions related to real estate, healthcare and technology companies. In 2010, Mr. Mindle co-founded Greystone Law Group LLP. Prior to co-founding Greystone Law Group LLP, Mr. Mindle was a partner in the Los Angeles officer of Orrick, Herrington & Sutcliffe LLP. Mr. Mindle is a veteran authority on real estate, finance and corporate transactions having represented real estate developers, private equity funds, pension funds, REITs, public and private companies and institutional lenders in connection with the acquisition and disposition of real estate assets, secured financing and joint ventures. During his three-decade career, Mr. Mindle has guided numerous start-up companies, mature organizations, pension funds, REITs and other public and private companies through a myriad of sophisticated transactions valued in billions of dollars. The third and final board position will look to be filled in the near future. Mark Branson has chosen to step down from his current position on the Board.공시 • Jun 24CannaPharmaRX, Inc. Announces CEO ChangesCannaPharmaRx, Inc. announced that the company has appointed a new CEO. Dean Medwid succeeds Domenic Colvin, who will stay with the company providing leadership and vision. Mr. Medwid assumed CEO duties earlier this month and will guide the company through its rapid growth phase. Mr. Medwid is a dynamic senior operations executive with more than thirty years of experience in both public and private markets with a focus on scalable process engineering, brand development and strategic partnerships. He has been recognized with numerous business awards and accolades, including Profit 100's Top 100 in Canada, five years in a row while a partner in Seattle's Best Coffee, additionally was a awarded the recognition of being one of Vancouver's Top 40 Under 40. Mr. Medwid recently exited his prior company in the retail cannabis sector and looks forward to bringing that background to the company as they target new revenue opportunities this year. His strengths include driving growth through the expansion of market segments and geography resulting in multi-year growth. Mr. Medwid also has extensive experience creating internal processes for departmental budgets, technology standards and human resource policies resulting in an engaged workforce as well as developing corporate governance aligned to generally accepted accounting principles. Mr. Medwid has a demonstrated history of increasing corporate performance through the management of process design, customer relationships, strategic planning along with a focused initiative of data-driven change management and utilized these skills as President of other successful publicly traded companies with operations in multiple countries.공시 • Jan 12CannaPharmaRx Receives Canada Revenue Agency (CRA) License As Final Step to Bringing Facility Into Production With Annual Revenues of Over $30 Million ExpectedCannaPharmaRx, Inc. announced that it has received its CRA license. A company can start producing cannabis products after receiving licensing from both the CRA and Health Canada. CannaPharmaRx can now begin business activities relating to the production and sale of cannabis. The license is valid for up to two years. CannaPharmaRx is now authorized to grow cannabis and sell wholesale to other licensed producers throughout Canada. The CRA oversees regulation of cannabis products including the production, possession, removal, sale and distribution of cannabis as well as impose proper excise duties and taxes on cannabis products. Now that both licenses are approved the company anticipates completing the first harvest during the current quarter with estimated annual revenue over $30 million.공시 • Dec 22+ 2 more updatesCannaPharmaRx, Inc Receives Cultivation License from Health Canada and Projects 2023 Revenue over $30 MillionCannaPharmaRx, Inc. announced Health Canada has issued a cultivation license to the Company. As a result, CannaPharmaRx may now legally grow cannabis and sell its crop to other licensed producers and licensed wholesalers throughout Canada. Health Canada is the department of the federal government of Canada responsible for national health policy. It approves and oversees the production of all cannabis products and is the licensing authority for all companies involved in the cannabis industry. Health Canada requires that all cannabis products meet federal regulatory requirements before they can be sold in Canada. The new license, denominated LIC-3JCQW6DIU0, is among the final major steps prior to production. This type of standard cultivation license is a prerequisite for licensed cannabis cultivators wanting to build and grow in a large-scale facility in order to expand their enterprise. Approval of the cultivation license allows the company to reasonably project completion of its initial first harvest and commence sales from the crop during First Quarter 2023 resulting in estimated 12 month revenues of $30 million.공시 • Nov 15CannaPharmaRX, Inc. announced delayed 10-Q filingOn 11/14/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 13CannaPharmaRX, Inc. announced delayed 10-Q filingOn 08/12/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/16/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 01CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 03/31/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Feb 11CannaPharmaRX, Inc. (OTCPK:CPMD) signed a letter of intent to acquire Operating Cannabis Facility Located in Braman, Oklahoma.CannaPharmaRX, Inc. (OTCPK:CPMD) signed a letter of intent to acquire Operating Cannabis Facility Located in Braman, Oklahoma on February 10, 2022. The purchase will be completed via a secured note and will include the transfer of licenses. The transaction is expected to close prior to March 31, 2022.공시 • Jun 09An unknown buyer entered in an agreement to acquire Hanover, Ontario Facility for CAD 2 million.An unknown buyer entered in an agreement to acquire Hanover, Ontario Facility for CAD 2 million on June 8, 2021. The proceeds of the sale will provide working capital, allowing the facility to become production ready in a short period of time. Senior management unanimously agreed a sale was most beneficial for the company and its stakeholders. The deal is expected to close on June 30, 2021.공시 • Apr 03CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 04/01/2021, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Jan 29CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a definitive agreement to acquire Assets and Facilities Located in Saskatoon, Saskatchewan for CAD 12 million.CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a definitive agreement to acquire Assets and Facilities Located in Saskatoon, Saskatchewan for CAD 12 million on January 18, 2021. The purchase price is subject to adjustments. CannaPharmaRX will pay the purchase price for the facility which means the sum of: (i) CAD 12 million and (ii) the CannaPharmaRX share of the option purchase price, not including goods and services tax. The payment schedule for the purchase price will be a deposit of CAD 0.1 million will be paid on execution of the agreement, CAD 5.9 million, plus 50% of the share of the option purchase price, plus the deposit, together with any goods and services tax thereon, subject to adjustments as hereinafter described, shall be paid to the seller’s solicitor on or before the closing date; then CAD 3 million plus the remaining 50% of the share of the option purchase price, together with any goods and services tax thereon, shall be paid within 3 Business Days of the Cultivation Licensing Approval Date; and then CAD 3 million together with any goods and services tax thereon, shall be paid within 3 Business Days of the Processing Licensing Approval Date. The transaction is subject to satisfaction of due diligence, board approval and certain closing conditions. The transaction is expected to close in February 2021.공시 • Jan 13CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a Purchase and Sale Agreement to acquire assets and facilities in Cremona AB for CAD 12 million.CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a Purchase and Sale Agreement to acquire assets and facilities in Cremona AB for CAD 12 million on January 7, 2021. The company will pay the “Purchase Price” for the facility which means the sum of: (i) CAD 12 million and (ii) the Purchaser’s Share of the Option Purchase Price, not including Goods and Services Tax. The payment schedule for the Purchase Price will be a deposit of CAD 0.1 million paid on execution of the PSA, the CAD 5.9 million, plus 50% of the Purchaser’s Share of the Option Purchase Price, plus the deposit, together with any Goods and Services Tax thereon, subject to adjustments as hereinafter described, shall be paid to the Seller’s solicitor on or before the closing date; then CAD 3 million plus the remaining 50% of the Purchaser’s Share of the Option Purchase Price, together with any Goods and Services Tax thereon, shall be paid within 3 Business Days of the Cultivation Licensing Approval Date; and then CAD 3 million, together with any Goods and Services Tax thereon, shall be paid within 3 Business Days of the Processing Licensing Approval Date. The transaction is subject to certain closing conditions and is scheduled to close in February 2021.공시 • Aug 19CannaPharmaRX, Inc. announced that it has received $3 million in funding from Triton Funds LLCCannaPharmaRX, Inc. (OTCPK:CPMD) announced that it has received $3,000,000 in a round of funding from new investor Triton Funds LLC on August 18, 2020.공시 • Aug 15CannaPharmaRX, Inc. announced delayed 10-Q filingOn 08/14/2020, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jul 07CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a purchase agreement to acquire Cannabis Production Facility in Cathedral City, California from Bristol Capital Advisors, LLC for $10 million.CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a purchase agreement to acquire Cannabis Production Facility in Cathedral City, California from Bristol Capital Advisors, LLC for $10 million on June 24, 2020. The acquisition is anticipated to close during the next 45 days, subject to CannapharmaRx receiving appropriate funding. Bennett J. Yankowitz of Shumaker Mallory LLP acted as legal advisor to Bristol, Joshua D. Brinen of Brinen & Associates, LLC acted as legal advisor to CannaPharmaRX.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 CPMD 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: CPMD 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장CannaPharmaRX 배당 수익률 vs 시장CPMD의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (CPMD)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Pharmaceuticals)2.2%분석가 예측 (CPMD) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 CPMD 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 CPMD 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 CPMD 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: CPMD 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/18 22:27종가2026/05/18 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스CannaPharmaRX, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jan 14Cannapharmarx, Inc. Announces Resignation of Director Rick Orman, Effective January 8, 2026CannaPharmaRX, Inc. announced that on January 8, 2026, Rick Orman informed the Board of Directors of his resignation as a member of the Board effective immediately. Mr. Orman's resignation from the Board did not indicate it was the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies, or practices of the Company.
공시 • Aug 22Cannapharmarx, Inc. Announces Revenue Guidance for Third Quarter 2025CannaPharmaRX, Inc. announced revenue guidance for third quarter 2025. The company projects revenues of approximately CAD 1,050,000, with the anticipation of additional shipments before the end of September. This forecast may vary slightly depending on fluctuations in the Euro-to-Canadian Dollar exchange rate.
공시 • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/16/2025, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 02CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 04/01/2025, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Jun 06CannaPharmaRX, Inc. Announces CEO ChangesCannaPharmaRx, Inc. announced that the company has appointed a new CEO. Dean Medwid succeeds Domenic Colvin, who will stay with the company providing leadership and vision. Mr. Medwid assumed CEO duties earlier this month and will guide the company through its rapid growth phase. Mr. Medwid is a dynamic senior operations executive with more than thirty years of experience in both public and private markets with a focus on scalable process engineering, brand development and strategic partnerships. He has been recognized with numerous business awards and accolades, including Profit 100's Top 100 in Canada, five years in a row while a partner in Seattle's Best Coffee, additionally was a awarded the recognition of being one of Vancouver's Top 40 Under 40. Mr. Medwid recently exited his prior company in the retail cannabis sector and looks forward to bringing that background to the company as they target new revenue opportunities this year. His strengths include driving growth through the expansion of market segments and geography resulting in multi-year growth. Mr. Medwid also has extensive experience creating internal processes for departmental budgets, technology standards and human resource policies resulting in an engaged workforce as well as developing corporate governance aligned to generally accepted accounting principles. Mr. Medwid has a demonstrated history of increasing corporate performance through the management of process design, customer relationships, strategic planning along with a focused initiative of data-driven change management and utilized these skills as President of other successful publicly traded companies with operations in multiple countries.
공시 • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/15/2024, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Mar 28CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 03/27/2024, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Nov 15CannaPharmaRX, Inc. announced delayed 10-Q filingOn 11/14/2023, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Oct 15CannaPharmaRX, Inc. Announces Executive ChangesEffective October 13, 2023, John Cassels is being replaced as the Chief Financial Officer (“CFO”) of CannPharmaRX, Inc. effective June 1, 2023. There was no disagreement between and Mr. Cassels on any matter related to operations, policies or practices that led to Mr. Cassels’s replacement as CFO. Effective October 13, 2023, Board of Directors has determined to appoint Oliver Foeste as Chief Financial Officer. Mr. Foeste has consented to such appointment. Mr. Foeste is the founder and Managing Partner of Invictus Accounting Group LLP and has significant executive, director, finance, and public company compliance experience across a number of industry sectors including cannabis and nutraceuticals. Prior to Invictus, Mr. Foeste was in senior finance and accounting roles at TSX, TSXV, and NYSE listed issuers, and earned his CPA at Deloitte and a boutique tax advisory firm.
공시 • Aug 26CannaPharmaRx Expands Board of DirectorsCannaPharmaRX, Inc. announced that it has expanded its board of directors from three seats to five. The board deemed this expansion was in the best interest of the corporation as it coincides with an expansion of operations. The following person(s) were elected to the Board to fill the newly created directorships until the next annual meeting of stockholders of the corporation: Mr. Anthony Panek, age 38, is a corporate mergers and acquisitions attorney and venture capital investor with expertise in capital raising formation and growing businesses. He has worked with private equity and venture capital funds to allocate capital to emerging growth companies and works with emerging growth companies, both public and private, to raise capital and acquire assets and corporate talent. He has been an investor in many emerging growth companies and private funds investing in similar companies. He works with companies from a business and legal perspective to navigate and manage growth challenges facing emerging growth companies and helping companies complying with their SEC reporting obligations. He completed the Venture Capital Certificate Program at Startup@Berkeley Law. Mr. Panek was selected to serve on the Company's Board based upon his experience as an attorney and venture capital and private equity investor helping emerging companies raise capital, comply with SEC reporting and governance requirements, and his work with other cannabis companies. Mr. Adam Mindle, age 52, is a transactional attorney with extensive experience in structuring, negotiating and documenting sophisticated joint ventures, secured financing and mergers and acquisitions related to real estate, healthcare and technology companies. In 2010, Mr. Mindle co-founded Greystone Law Group LLP. Prior to co-founding Greystone Law Group LLP, Mr. Mindle was a partner in the Los Angeles officer of Orrick, Herrington & Sutcliffe LLP. Mr. Mindle is a veteran authority on real estate, finance and corporate transactions having represented real estate developers, private equity funds, pension funds, REITs, public and private companies and institutional lenders in connection with the acquisition and disposition of real estate assets, secured financing and joint ventures. During his three-decade career, Mr. Mindle has guided numerous start-up companies, mature organizations, pension funds, REITs and other public and private companies through a myriad of sophisticated transactions valued in billions of dollars. The third and final board position will look to be filled in the near future. Mark Branson has chosen to step down from his current position on the Board.
공시 • Jun 24CannaPharmaRX, Inc. Announces CEO ChangesCannaPharmaRx, Inc. announced that the company has appointed a new CEO. Dean Medwid succeeds Domenic Colvin, who will stay with the company providing leadership and vision. Mr. Medwid assumed CEO duties earlier this month and will guide the company through its rapid growth phase. Mr. Medwid is a dynamic senior operations executive with more than thirty years of experience in both public and private markets with a focus on scalable process engineering, brand development and strategic partnerships. He has been recognized with numerous business awards and accolades, including Profit 100's Top 100 in Canada, five years in a row while a partner in Seattle's Best Coffee, additionally was a awarded the recognition of being one of Vancouver's Top 40 Under 40. Mr. Medwid recently exited his prior company in the retail cannabis sector and looks forward to bringing that background to the company as they target new revenue opportunities this year. His strengths include driving growth through the expansion of market segments and geography resulting in multi-year growth. Mr. Medwid also has extensive experience creating internal processes for departmental budgets, technology standards and human resource policies resulting in an engaged workforce as well as developing corporate governance aligned to generally accepted accounting principles. Mr. Medwid has a demonstrated history of increasing corporate performance through the management of process design, customer relationships, strategic planning along with a focused initiative of data-driven change management and utilized these skills as President of other successful publicly traded companies with operations in multiple countries.
공시 • Jan 12CannaPharmaRx Receives Canada Revenue Agency (CRA) License As Final Step to Bringing Facility Into Production With Annual Revenues of Over $30 Million ExpectedCannaPharmaRx, Inc. announced that it has received its CRA license. A company can start producing cannabis products after receiving licensing from both the CRA and Health Canada. CannaPharmaRx can now begin business activities relating to the production and sale of cannabis. The license is valid for up to two years. CannaPharmaRx is now authorized to grow cannabis and sell wholesale to other licensed producers throughout Canada. The CRA oversees regulation of cannabis products including the production, possession, removal, sale and distribution of cannabis as well as impose proper excise duties and taxes on cannabis products. Now that both licenses are approved the company anticipates completing the first harvest during the current quarter with estimated annual revenue over $30 million.
공시 • Dec 22+ 2 more updatesCannaPharmaRx, Inc Receives Cultivation License from Health Canada and Projects 2023 Revenue over $30 MillionCannaPharmaRx, Inc. announced Health Canada has issued a cultivation license to the Company. As a result, CannaPharmaRx may now legally grow cannabis and sell its crop to other licensed producers and licensed wholesalers throughout Canada. Health Canada is the department of the federal government of Canada responsible for national health policy. It approves and oversees the production of all cannabis products and is the licensing authority for all companies involved in the cannabis industry. Health Canada requires that all cannabis products meet federal regulatory requirements before they can be sold in Canada. The new license, denominated LIC-3JCQW6DIU0, is among the final major steps prior to production. This type of standard cultivation license is a prerequisite for licensed cannabis cultivators wanting to build and grow in a large-scale facility in order to expand their enterprise. Approval of the cultivation license allows the company to reasonably project completion of its initial first harvest and commence sales from the crop during First Quarter 2023 resulting in estimated 12 month revenues of $30 million.
공시 • Nov 15CannaPharmaRX, Inc. announced delayed 10-Q filingOn 11/14/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 13CannaPharmaRX, Inc. announced delayed 10-Q filingOn 08/12/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/16/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 01CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 03/31/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Feb 11CannaPharmaRX, Inc. (OTCPK:CPMD) signed a letter of intent to acquire Operating Cannabis Facility Located in Braman, Oklahoma.CannaPharmaRX, Inc. (OTCPK:CPMD) signed a letter of intent to acquire Operating Cannabis Facility Located in Braman, Oklahoma on February 10, 2022. The purchase will be completed via a secured note and will include the transfer of licenses. The transaction is expected to close prior to March 31, 2022.
공시 • Jun 09An unknown buyer entered in an agreement to acquire Hanover, Ontario Facility for CAD 2 million.An unknown buyer entered in an agreement to acquire Hanover, Ontario Facility for CAD 2 million on June 8, 2021. The proceeds of the sale will provide working capital, allowing the facility to become production ready in a short period of time. Senior management unanimously agreed a sale was most beneficial for the company and its stakeholders. The deal is expected to close on June 30, 2021.
공시 • Apr 03CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 04/01/2021, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Jan 29CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a definitive agreement to acquire Assets and Facilities Located in Saskatoon, Saskatchewan for CAD 12 million.CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a definitive agreement to acquire Assets and Facilities Located in Saskatoon, Saskatchewan for CAD 12 million on January 18, 2021. The purchase price is subject to adjustments. CannaPharmaRX will pay the purchase price for the facility which means the sum of: (i) CAD 12 million and (ii) the CannaPharmaRX share of the option purchase price, not including goods and services tax. The payment schedule for the purchase price will be a deposit of CAD 0.1 million will be paid on execution of the agreement, CAD 5.9 million, plus 50% of the share of the option purchase price, plus the deposit, together with any goods and services tax thereon, subject to adjustments as hereinafter described, shall be paid to the seller’s solicitor on or before the closing date; then CAD 3 million plus the remaining 50% of the share of the option purchase price, together with any goods and services tax thereon, shall be paid within 3 Business Days of the Cultivation Licensing Approval Date; and then CAD 3 million together with any goods and services tax thereon, shall be paid within 3 Business Days of the Processing Licensing Approval Date. The transaction is subject to satisfaction of due diligence, board approval and certain closing conditions. The transaction is expected to close in February 2021.
공시 • Jan 13CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a Purchase and Sale Agreement to acquire assets and facilities in Cremona AB for CAD 12 million.CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a Purchase and Sale Agreement to acquire assets and facilities in Cremona AB for CAD 12 million on January 7, 2021. The company will pay the “Purchase Price” for the facility which means the sum of: (i) CAD 12 million and (ii) the Purchaser’s Share of the Option Purchase Price, not including Goods and Services Tax. The payment schedule for the Purchase Price will be a deposit of CAD 0.1 million paid on execution of the PSA, the CAD 5.9 million, plus 50% of the Purchaser’s Share of the Option Purchase Price, plus the deposit, together with any Goods and Services Tax thereon, subject to adjustments as hereinafter described, shall be paid to the Seller’s solicitor on or before the closing date; then CAD 3 million plus the remaining 50% of the Purchaser’s Share of the Option Purchase Price, together with any Goods and Services Tax thereon, shall be paid within 3 Business Days of the Cultivation Licensing Approval Date; and then CAD 3 million, together with any Goods and Services Tax thereon, shall be paid within 3 Business Days of the Processing Licensing Approval Date. The transaction is subject to certain closing conditions and is scheduled to close in February 2021.
공시 • Aug 19CannaPharmaRX, Inc. announced that it has received $3 million in funding from Triton Funds LLCCannaPharmaRX, Inc. (OTCPK:CPMD) announced that it has received $3,000,000 in a round of funding from new investor Triton Funds LLC on August 18, 2020.
공시 • Aug 15CannaPharmaRX, Inc. announced delayed 10-Q filingOn 08/14/2020, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jul 07CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a purchase agreement to acquire Cannabis Production Facility in Cathedral City, California from Bristol Capital Advisors, LLC for $10 million.CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a purchase agreement to acquire Cannabis Production Facility in Cathedral City, California from Bristol Capital Advisors, LLC for $10 million on June 24, 2020. The acquisition is anticipated to close during the next 45 days, subject to CannapharmaRx receiving appropriate funding. Bennett J. Yankowitz of Shumaker Mallory LLP acted as legal advisor to Bristol, Joshua D. Brinen of Brinen & Associates, LLC acted as legal advisor to CannaPharmaRX.